420 related articles for article (PubMed ID: 23684315)
1. ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice.
Liraz O; Boehm-Cagan A; Michaelson DM
Mol Neurodegener; 2013 May; 8():16. PubMed ID: 23684315
[TBL] [Abstract][Full Text] [Related]
2. Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.
Salomon-Zimri S; Glat MJ; Barhum Y; Luz I; Boehm-Cagan A; Liraz O; Ben-Zur T; Offen D; Michaelson DM
J Alzheimers Dis; 2016 Jun; 53(4):1443-58. PubMed ID: 27372644
[TBL] [Abstract][Full Text] [Related]
3. Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade.
Inbar D; Belinson H; Rosenman H; Michaelson DM
Neurodegener Dis; 2010; 7(1-3):16-23. PubMed ID: 20160452
[TBL] [Abstract][Full Text] [Related]
4. ApoE4 induces synaptic and ERG impairments in the retina of young targeted replacement apoE4 mice.
Antes R; Ezra-Elia R; Weinberger D; Solomon A; Ofri R; Michaelson DM
PLoS One; 2013; 8(5):e64949. PubMed ID: 23741431
[TBL] [Abstract][Full Text] [Related]
5. ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.
Belinson H; Michaelson DM
J Neural Transm (Vienna); 2009 Nov; 116(11):1427-34. PubMed ID: 19370389
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice.
Dolejší E; Liraz O; Rudajev V; Zimčík P; Doležal V; Michaelson DM
J Neurochem; 2016 Feb; 136(3):503-9. PubMed ID: 26526158
[TBL] [Abstract][Full Text] [Related]
7. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits.
Belinson H; Lev D; Masliah E; Michaelson DM
J Neurosci; 2008 Apr; 28(18):4690-701. PubMed ID: 18448646
[TBL] [Abstract][Full Text] [Related]
8. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol.
Kariv-Inbal Z; Yacobson S; Berkecz R; Peter M; Janaky T; Lütjohann D; Broersen LM; Hartmann T; Michaelson DM
J Alzheimers Dis; 2012; 28(3):667-83. PubMed ID: 22057027
[TBL] [Abstract][Full Text] [Related]
9. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
Boehm-Cagan A; Michaelson DM
J Neurosci; 2014 May; 34(21):7293-301. PubMed ID: 24849361
[TBL] [Abstract][Full Text] [Related]
10. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
Brecht WJ; Harris FM; Chang S; Tesseur I; Yu GQ; Xu Q; Dee Fish J; Wyss-Coray T; Buttini M; Mucke L; Mahley RW; Huang Y
J Neurosci; 2004 Mar; 24(10):2527-34. PubMed ID: 15014128
[TBL] [Abstract][Full Text] [Related]
11. Extra-Hippocampal Learning Deficits in Young Apolipoprotein E4 Mice and Their Synaptic Underpinning.
Har-Paz I; Roisman N; Michaelson DM; Moran A
J Alzheimers Dis; 2019; 72(1):71-82. PubMed ID: 31561365
[TBL] [Abstract][Full Text] [Related]
12. Hippocampus-related cognitive impairments in young apoE4 targeted replacement mice.
Salomon-Zimri S; Boehm-Cagan A; Liraz O; Michaelson DM
Neurodegener Dis; 2014; 13(2-3):86-92. PubMed ID: 24080852
[TBL] [Abstract][Full Text] [Related]
13. The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo.
Salomon-Zimri S; Koren A; Angel A; Ben-Zur T; Offen D; Michaelson DM
Curr Alzheimer Res; 2019; 16(4):281-292. PubMed ID: 30819082
[TBL] [Abstract][Full Text] [Related]
14. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.
Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R
J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429
[TBL] [Abstract][Full Text] [Related]
15. An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo.
Luz I; Liraz O; Michaelson DM
Curr Alzheimer Res; 2016 Jun; 13(8):918-29. PubMed ID: 27040139
[TBL] [Abstract][Full Text] [Related]
16. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.
Tachibana M; Holm ML; Liu CC; Shinohara M; Aikawa T; Oue H; Yamazaki Y; Martens YA; Murray ME; Sullivan PM; Weyer K; Glerup S; Dickson DW; Bu G; Kanekiyo T
J Clin Invest; 2019 Mar; 129(3):1272-1277. PubMed ID: 30741718
[TBL] [Abstract][Full Text] [Related]
17. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.
Levi O; Dolev I; Belinson H; Michaelson DM
J Neurochem; 2007 Nov; 103(3):1031-40. PubMed ID: 17666042
[TBL] [Abstract][Full Text] [Related]
18. ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.
Boehm-Cagan A; Bar R; Liraz O; Bielicki JK; Johansson JO; Michaelson DM
J Alzheimers Dis; 2016 Oct; 54(3):1219-1233. PubMed ID: 27567858
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
Buttini M; Yu GQ; Shockley K; Huang Y; Jones B; Masliah E; Mallory M; Yeo T; Longo FM; Mucke L
J Neurosci; 2002 Dec; 22(24):10539-48. PubMed ID: 12486146
[TBL] [Abstract][Full Text] [Related]
20. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc.
Harris FM; Brecht WJ; Xu Q; Mahley RW; Huang Y
J Biol Chem; 2004 Oct; 279(43):44795-801. PubMed ID: 15322121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
